High-Dose Taxol, Cyclophosphamide, and Cisplatin with Stem Cell Support in the Treatment of Metastatic Breast Cancer

  1. Svetislava J. Vukelja MD1,
  2. W. Jeffery Baker MD2,
  3. Miriam Y.J. Atkins MD3,
  4. Nicole Lee MD4,
  5. Joseph J. Stephenson MD3

Article first published online: 31 JAN 2003

DOI: 10.1046/j.1524-4741.1998.430165.x

Issue

The Breast Journal

The Breast Journal

Volume 4, Issue 3, pages 165–170, May 1998

Additional Information

How to Cite

Vukelja, S. J., Baker, W. J., Atkins, M. Y., Lee, N. and Stephenson, J. J. (1998), High-Dose Taxol, Cyclophosphamide, and Cisplatin with Stem Cell Support in the Treatment of Metastatic Breast Cancer. The Breast Journal, 4: 165–170. doi: 10.1046/j.1524-4741.1998.430165.x

Author Information

  1. 1

    Tyler Cancer Center, Tyler, Texas

  2. 2

    Saint Francis/Mount Sinai Regional Cancer Center, Hartford, Connecticut

  3. 3

    Hematology/Oncology Service, Brooke Army Medical Center, Fort Sam Houston, Texas

  4. 4

    Hematology/Oncology Service, Walter Reed Army Medical Center, Washington, D.C.

*Address correspondence and reprint request to: Svetislava J. Vukelja, MD, Tyler Cancer Center, 910 East Houston, Suite 100, Tyler, TX 75702, U.S.A.

Publication History

  1. Issue published online: 31 JAN 2003
  2. Article first published online: 31 JAN 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (715K)

Keywords:

  • high-dose;
  • chemotherapy;
  • stem;
  • cell;
  • metastatic;
  • breast;
  • cancer

Abstract: Fifty-four patients with metastatic breast cancer were treated with high-dose paclitaxel (200 mg/m2), cyclophosphamide (5,625 mg/m2) and cisplatin (165 mg/m2) with autologous stem cell support. Median age of the group was 43 years (range 24–58); half of the patients had received ≥2 prior regimens for metastatic disease. The interval between completion of standard therapy and initiation of high-dose therapy was less than 60 days. Four patients were in complete remission (CR) prior to high-dose chemotherapy. Among patients with measurable disease 15 (44%) attained CR after high-dose chemotherapy. At a median follow-up of 19.2 months, 13 patients continue in CR and 18 patients (36%) are free from progressive disease. Thirty-two patients have relapsed, 14 of whom developed disease at new sites. There was no difference in pattern of relapse between patients receiving bone marrow versus peripheral blood stem-cell rescue. Overall, toxicities of this high-dose chemotherapy regimen were manageable. Four patients (7%) died of treatment-related complications. Two died of diffuse alveolar hemorrhage, one of congestive heart failure, and one of systemic fungal infection. Neurologic toxicity was mild and might have been ameliorated by supplemental pyridoxine.

Get PDF (715K)